(redirected from Montelukast sodium)
Also found in: Medical.


A drug that reduces the inflammatory response by acting as a leukotriene receptor antagonist, and is used to treat the signs and symptoms of asthma.

[monte-, of unknown origin + -lukast, leukotriene receptor antagonist suff.; see zafirlukast.]


n montelukast m
References in periodicals archive ?
a subsidiary of Ajanta Pharma Limited, India, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg), generic versions of SINGULAIR Tablets and SINGULAIR Chewable Tablets, respectively.
Eosinophilic cystitis:successful long-term treatment with montelukast sodium.
In 1998, montelukast sodium tablets (10mg) and chewable tablets (5mg) were approved by FDA to the market with the trade name ""Singulair"".
In the Kingdom, a new line of asthma control drugs known as montelukast sodium is used to prevent asthma attacks in adults and children as young as 12 months old.
The woman was also taking two prescription drugs, fluoxetine and montelukast sodium, both of which have been reported to cause hepatitis.
However, data show that patients who used montelukast sodium (Singulair) continue to experience postexercise declines of lung function averaging 15% to 20% compared with a control group experiencing a 30% drop in [FEV.
Montelukast sodium, discovered by Merck Frosst Canada Inc.
Reddy's Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair[R] (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.
a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market.
The patient was aggressively treated for laryngopharyngeal reflux and allergy with esomeprazole, nizatidine, montelukast sodium, and fluticasone.
The analysis showed that the median time to an asthma-related inpatient stay or emergency room visit in the first year after initiating asthma controller monotherapy was similar for 3,080 patients who started montelukast sodium treatment and 3,080 matched patients who started fluticasone propionate treatment, said Dr.